Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yuman Fong

Surgical Oncology Duarte, CA Medical Doctor

NPI 1346231735 CMS profile 288031

1500 Duarte Rd, Duarte, CA 91010

Open in the dashboard

General payments

$86,979

101 records reported · program years 2019–2025

Research payments

$2,000

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yuman Fong of Duarte, CA is reported in the CMS Open Payments database as having received $86,979 across 101 general payments and $2,000 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Surgical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,291 15
2024 General $12,954 36
2023 General $10,439 5
2022 General $10,215 6
2021 General $2,432 9
2021 Research $2,000 1
2020 General $26,329 16
2019 General $11,319 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yuman Fong
  • Surgical Oncology median
  • Middle half of Surgical Oncology
  • National median

In program year 2025, general payments to Yuman Fong were reported at $13,291. Among 1,137 Surgical Oncology profiles paid that year, the median was $288 and the middle half received between $118 and $1,346.

Show as a table
Year Yuman Fong Surgical Oncology median Middle half National median
2019 $11,319 $236 $86–$1,064 $163
2020 $26,329 $130 $47–$648 $114
2021 $2,432 $160 $53–$943 $132
2022 $10,215 $199 $76–$782 $149
2023 $10,439 $246 $95–$854 $160
2024 $12,954 $271 $106–$1,123 $164
2025 $13,291 $288 $118–$1,346 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $42,598 50 payments
  2. Covidien LP $34,840 22 payments
  3. CMR Surgical, Inc. $5,486 5 payments
  4. Olympus Corporation $1,140 1 payment
  5. Stryker Corporation $896 5 payments
  6. Intuitive Surgical, Inc. $423 3 payments
  7. Elucent Medical $418 1 payment
  8. Boehringer Ingelheim International GmbH $300 1 payment
  9. Galvanize Therapeutics, Inc $198 1 payment
  10. Dilon Technologies, Inc. $141 1 payment
  11. Other $537 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $46,000 8 payments
  2. Consulting Fee $27,859 12 payments
  3. Travel and Lodging $10,059 35 payments
  4. Food and Beverage $3,061 46 payments
Products named General payments · program years 2019–2025
  1. Versius Surgical System (Versius Plus) $5,486 5 payments
  2. 1588 HD 3 CHIP CAMERA $748 4 payments
  3. Da Vinci Surgical System $423 3 payments
  4. ALIYA SYSTEM $198 1 payment
  5. SPY TECHNOLOGY $148 1 payment
  6. ForceTriad $144 2 payments
  7. HEMOBLAST BELLOWS $141 1 payment
  8. Mira $107 2 payments
  9. General - Interventional Oncology $106 1 payment
  10. Endo GIA $85 1 payment
  11. Other $299 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $2,000 1 payment

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$52,476

Medicare's payments for the services billed

Medicare patients

122

Average age 72

Services billed

239

60 women, 62 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 48%
Arthritis 48%
Diabetes 35%
Ischemic heart disease 29%
Chronic kidney disease 22%
Depression 20%
Osteoporosis 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LUTATHERA
  • Novartis Pharmaceuticals Corporation $66
$66 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

102 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgical Oncology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record